USFDA concludes inspection of NATCO’s Pharma Division, Kothur
The company received seven observations in the Form-483
The company received seven observations in the Form-483
Sun Pharma gets 8 observations from USFDA for Halol facility
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
The company received one observation in the Form-483
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Ranks among the top 15% companies globally
The company received 1 (One) observation in the Form-483
Subscribe To Our Newsletter & Stay Updated